Latest Breaking News On - Raf v600 nsclc - Page 1 : comparemela.com

Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed.

United statesUniversity of pennsylvaniaCoreyj langerInternational lung cancer congressHospital of the university pennsylvaniaAbramson cancer centerAnnual international lung cancer congressRaf v600 nsclcPhase 2 pharos trial nct03915951